Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DZD8586 combination therapy in CLL/SLL
CTR20253197Phase 2Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of birelentinib, venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Oct 2025; status: active.
02
Drugs
birelentinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20253197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253197.